Global Biopharma R&D Productivity And Growth Ranking
Overall Decline In R&D Productivity Continued In 2019
An analysis of the R&D productivity of the world’s 30 largest public pharmaceutical companies reveals an overall drop in R&D productivity, but this should not hide the fact that some companies are still performing extremely well.
You may also be interested in...
The superior R&D and growth performance of mid-sized companies like Celgene, Gilead, or Biogen can be attributed to a number of factors such as the size of the R&D budget, portfolio focus, a good mix of internal and external innovation sourcing, but most importantly a strong culture, leadership, and the ability to attract the right people. Part 3 of Catenion’s review of pharma R&D productivity.
Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development.
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.